Holista CollTech Ltd (ASX:HCT) has secured global distribution rights for a supplement, sourced from algae that can enhance stem cell growth and promote its release.
Developed by renowned scientist Dr Stefano Scoglio. the Klamath algae (AFA) product “Klamax” includes two patented AFA extracts:
- Klamin, which has a high concentration of phenylethylamine (PEA), a powerful molecule endowed with neuromodulating, immune-enhancing and neuronal stem-cells promoting activities; and
- AphaMax, concentrating AFA-phycocyanins and endowed with strong antioxidants, anti-inflammatory, and somatic stem-cells promoting activities.
The Aphanizomenon Flos-aquae (AFA) algae is harvested from Klamath Lake in Oregon – considered to be the most pristine environment in North America after Alaska.
The algae’s unusual properties are due in part to the fact that it grows on the surface of the lake that sits on top of a 7,700-year bed of rich volcanic ash.
“When consumed, the Klamax product (which contains a proprietary blend of Klamin and AphaMax) effectively enhances general wellness and anti-aging health, by promoting and supporting a normal neurological, somatic and stem-cells physiology,” said Dr Scoglio, the Nobel Prize Nominee for Medicine this year.
Holista CEO Dr Rajen Manicka, said Holista intends to develop oral and transdermal preparations to be sold through network marketing platform, iGalen International Inc (iGalen), which has an agreement to source all its bio-pharmaceutical and dietary supplements products.
iGalen has more than 12,500 distributors worldwide, and intends to enter Australia and New Zealand, apart from United States, Canada, Malaysia, Singapore and Philippines.
“The AFA algae is highly sought after for its rejuvenative properties. We are delighted that Dr Scoglio has entrusted us to roll out this product for the global stem cell market, which is growing at a rapid pace. His many publications and exclusive ownership of key patents is going to be an asset in our attempts to take on this market,” said Dr Manicka.
In August 2017, Holista announced that it had secured the global rights for Emulin, an all-natural carbohydrates manager developed by two Nobel Prize nominees.
A month later it announced it was acquiring a 47% stake in iGalen from Dr Rajen for a nominal consideration of US$1 pending shareholder approval.
